220 related articles for article (PubMed ID: 29915391)
1. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
Brough R; Gulati A; Haider S; Kumar R; Campbell J; Knudsen E; Pettitt SJ; Ryan CJ; Lord CJ
Oncogene; 2018 Oct; 37(43):5701-5718. PubMed ID: 29915391
[TBL] [Abstract][Full Text] [Related]
2. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
3. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
4. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
Gupta P; Zhao H; Hoang B; Schwartz EL
Br J Cancer; 2022 Oct; 127(6):969-975. PubMed ID: 35752713
[TBL] [Abstract][Full Text] [Related]
5. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q; Ba-Alawi W; Deblois G; Cruickshank J; Duan S; Lima-Fernandes E; Haight J; Tonekaboni SAM; Fortier AM; Kuasne H; McKee TD; Mahmoud H; Kushida M; Cameron S; Dogan-Artun N; Chen W; Nie Y; Zhang LX; Vellanki RN; Zhou S; Prinos P; Wouters BG; Dirks PB; Done SJ; Park M; Cescon DW; Haibe-Kains B; Lupien M; Arrowsmith CH
Nat Commun; 2020 Aug; 11(1):4205. PubMed ID: 32826891
[TBL] [Abstract][Full Text] [Related]
6. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.
Bulanova D; Akimov Y; Senkowski W; Oikkonen J; Gall-Mas L; Timonen S; Elmadani M; Hynninen J; Hautaniemi S; Aittokallio T; Wennerberg K
Sci Adv; 2024 May; 10(21):eadj1564. PubMed ID: 38781347
[TBL] [Abstract][Full Text] [Related]
7. Co-expression and prognosis analyses of GLUT1-4 and RB1 in breast cancer.
Zhang X; Pang X; Zhang Z; Liu Q; Zhang H; Xiang Q; Cui Y
BMC Cancer; 2021 Sep; 21(1):1026. PubMed ID: 34525987
[TBL] [Abstract][Full Text] [Related]
8. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
[TBL] [Abstract][Full Text] [Related]
9. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
10. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics.
Lyu J; Yang EJ; Zhang B; Wu C; Pardeshi L; Shi C; Mou PK; Liu Y; Tan K; Shim JS
Nat Commun; 2020 Oct; 11(1):5105. PubMed ID: 33037191
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
13. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide relationships between TAF1 and histone acetyltransferases in Saccharomyces cerevisiae.
Durant M; Pugh BF
Mol Cell Biol; 2006 Apr; 26(7):2791-802. PubMed ID: 16537921
[TBL] [Abstract][Full Text] [Related]
15. Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.
Zhao H; Wang H; Bauzon F; Lu Z; Fu H; Cui J; Zhu L
J Biol Chem; 2016 May; 291(19):10201-9. PubMed ID: 26966181
[TBL] [Abstract][Full Text] [Related]
16. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
17. SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.
Fagan-Solis KD; Pentecost BT; Gozgit JM; Bentley BA; Marconi SM; Otis CN; Anderton DL; Schneider SS; Arcaro KF
J Cell Physiol; 2014 Sep; 229(9):1160-9. PubMed ID: 24443386
[TBL] [Abstract][Full Text] [Related]
18. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
19. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
20. PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor Prognosis in Triple-Negative Breast Cancer.
Cai YC; Yang H; Shan HB; Su HF; Jiang WQ; Shi YX
Dis Markers; 2021; 2021():8824589. PubMed ID: 34211613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]